title: A G protein is involved in the angiotensin AT2 receptor inhibition of the T-type calcium current in non-differentiated NG108-15 cells.
abstract: In non-differentiated NG108-15 cells, both angiotensin II (Ang II) (100 nM) and CGP 42112 (100 nM) decreased the T-type calcium current amplitude by 24 +/- 2% and 21 +/- 3%, respectively. cGMP is not a mediator of the Ang II effect, since loading of cells with 50 microM cGMP did not prevent the inhibitory effects of Ang II. The effects of Ang II involves a non-identified GTPase activity since incubation with GDP beta S (3 mM) completely reversed the inhibitory effect of Ang II while GTP gamma S mimicked its effect. However, Ang II binding was not affected by GTP gamma S, and the effect of Ang II was not modified in pertussis toxin-treated cells. The inhibitory effect of Ang II on the T-type Ca2+ current involves a phosphotyrosine phosphatase activity since sodium orthovanadate prevented the effects of Ang II, although microcystin-LR, a selective Ser/Thr phosphatase 1 and 2A inhibitor, did not modify the effect of Ang II. These results provide the first evidence of a modulation of membrane conductance by Ang II through the AT2 receptor and demonstrate the involvement of a phosphotyrosine phosphatase and a G protein in the AT2 transduction mechanism in NG108-15 cells. Moreover, our data suggest that phosphotyrosine phosphatase activation is proximal to receptor occupation, since sodium orthovanadate inhibits both GTPase activity and T-type current blockage induced by Ang II or CGP 42112, while GTP gamma S inhibition of the T-type calcium current is not impaired.
authors: Service of Endocrinology, Faculty of Medicine, University of Sherbrooke, Québec, Canada.
authors: B
authors: B
authors: Buisson
authors: L
authors: L
authors: Laflamme
authors: S P
authors: SP
authors: Bottari
authors: M
authors: M
authors: de Gasparo
authors: N
authors: N
authors: Gallo-Payet
authors: M D
authors: MD
authors: Payet
mesh_terms: D000804:Angiotensin II / Q000037:antagonists & inhibitors / Q000494:pharmacology*; D057911:Angiotensin Receptor Antagonists; D000818:Animals; D015220:Calcium Channels / Q000502:physiology*; D006152:Cyclic GMP / Q000494:pharmacology; D019204:GTP-Binding Proteins / Q000378:metabolism*; D005910:Glioma; D006822:Hybrid Cells; D007700:Kinetics; D008564:Membrane Potentials / Q000187:drug effects; D009447:Neuroblastoma; D009842:Oligopeptides / Q000494:pharmacology*; D018408:Patch-Clamp Techniques; D011945:Receptors, Angiotensin / Q000502:physiology*; D013997:Time Factors
chemical_list: D057911:Angiotensin Receptor Antagonists; D015220:Calcium Channels; D009842:Oligopeptides; D011945:Receptors, Angiotensin; D000804:Angiotensin II; C060894:CGP 42112A; D019204:GTP-Binding Proteins; D006152:Cyclic GMP